Research Study

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study
Principal Investigator 
Nasreen Khalil

Overview

Body Locations and Systems 
Pulmonary Fibrosis
ClinicalTrials.gov# 
NCT02345070
Status 
Closed to Recruitment
Study Start/End 
Jun 16, 2016 to Apr 30, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Gurjind Raid, Research Coordinator
Phone 
604-875-5091
Purpose of Study 

Primary Objective:

To evaluate, in comparison with placebo, the efficacy of 2 dose levels of SAR156597 administered subcutaneously during 52 weeks on lung function of patients with Idiopathic Pulmonary Fibrosis (IPF).

Secondary Objectives:

To evaluate the efficacy of 2 dose levels of SAR156597 compared to placebo on IPF disease progression.

To evaluate the safety of 2 dose levels of SAR156597 compared to placebo in patients with IPF.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.